Evidence map›Paper›PMID 38955670›Full record

ArticleInternational journal for quality in health care : journal of the International Society for Quality in Health Care2024

Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill.

Rebecca J Wessel, Christina G Rivera, Sara E Ausman, Nathaniel Martin, Shienna A Braga, Natalie T Hagy, Lindsay N Moreland-Head, Omar M Abu Saleh, Ognjen Gajic, Paul J Jannetto and 1 more

Abstract read
In one paragraph

Article in International journal for quality in health care : journal of the International Society for Quality in Health Care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rebecca J WesselStrategy Department, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Christina G RiveraDepartment of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Sara E AusmanDepartment of Pharmacy, Mayo Clinic Health System, 733 W Clairemont Ave, Eau Claire, WI 54701, United States.
Nathaniel MartinDepartment of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Shienna A BragaDepartment of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Natalie T HagyDepartment of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Lindsay N Moreland-HeadIndiana University School of Medicine, 340 West 10th Street, Fairbanks Hall, Suite 6200, Indianapolis, IN 46202, United States.
Omar M Abu SalehDivision of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Ognjen GajicDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Paul J JannettoDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
Erin F BarretoDepartment of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.

Funding

Beta-lactam individualization for critically ill patientsK23AI143882 · NIAID · MAYO CLINIC ROCHESTER · PI BARRETO, ERIN FRAZEE · 2020 to 2024
$986k
Mayo Clinic Division of Public Health, Infectious Diseases and Occupational MedicineNational Institute of Allergy and Infectious Diseases of the National Institutes of Health K23AI143882NIAID NIH HHS K23 AI143882
6 · The paper itself

Abstract

Beta-lactam antibiotics are widely used in the intensive care unit due to their favorable effectiveness and safety profiles. Beta-lactams given to patients with sepsis must be delivered as soon as possible after infection recognition (early), treat the suspected organism (appropriate), and be administered at a dose that eradicates the infection (adequate). Early and appropriate antibiotic delivery occurs in >90% of patients, but less than half of patients with sepsis achieve adequate antibiotic exposure. This project aimed to address this quality gap and improve beta-lactam adequacy using the Define, Measure, Analyze, Improve, and Control Lean Six Sigma quality improvement framework. A multidisciplinary steering committee was formed, which completed a stakeholder analysis to define the gap in practice. An Ishikawa cause and effect (Fishbone) diagram was used to identify the root causes and an impact/effort grid facilitated prioritization of interventions. An intervention that included bundled education with the use of therapeutic drug monitoring (TDM; i.e. drug-level testing) was projected to have the highest impact relative to the amount of effort and selected to address beta-lactam inadequacy in the critically ill. The education and TDM intervention were deployed through a Plan, Do, Study, Act cycle. In the 3 months after "go-live," 54 episodes of beta-lactam TDM occurred in 41 unique intensive care unit patients. The primary quality metric of beta-lactam adequacy was achieved in 94% of individuals after the intervention. Ninety-four percent of clinicians gauged the education provided as sufficient. The primary counterbalance of antimicrobial days of therapy, a core antimicrobial stewardship metric, was unchanged over time (favorable result; P = .73). Application of the Define, Measure, Analyze, Improve, and Control Lean Six Sigma quality improvement framework effectively improved beta-lactam adequacy in critically ill patients. The approach taken in this quality improvement project is widely generalizable to other drugs, drug classes, or settings to increase the adequacy of drug exposure.

Indexed as

Anti-Bacterial Agentsbeta-LactamsCritical IllnessIntensive Care UnitsQuality ImprovementTotal Quality ManagementDrug MonitoringHumansSepsisAnti-Bacterial Agentsbeta-Lactamsbeta-lactamsLean Six Sigmamedication deliveryquality improvementtherapeutic drug monitoring

Identifiers

PMID38955670
PMCPMC11439991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.